Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

Por Paraiso, K H T, Fedorenko, I V, Cantini, L P, Munko, A C, Hall, M, Sondak, V K, Messina, J L, Flaherty, K T, Smalley, K S M
Publicado em 2010

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

Por Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Publicado em 2012

Genetic variations of the EVER genes, cutaneous human papillomavirus (HPV) infection, and squamous cell carcinoma of the skin

Por Hampras, S.S., Rollison, D.E., Tommasino, M., Gheit, T., Schabath, M.B., Messina, J.L., Fenske, N.A., Cherpelis, B.S., Sondak, V.K., Iannacone, M.R., Schmitt, M., Pawlita, M.
Publicado no Br J Dermatol (2015)